Prior Benzodiazepine Exposure and Benzodiazepine Treatment Outcome

Karl Rickels and Ellen W. Freeman

Published: November 30, 2000

Article Abstract

Background: We examined discontinuation symptomsfollowing brief benzodiazepine therapy (8 weeks) and intermittentbenzodiazepine therapy (2 weeks with at least 2 weeks withoutdrug) and associations with prior benzodiazepine use. Thehypothesis was that prior benzodiazepine use would predisposepatients to more severe discontinuation symptoms.

Method: Data were drawn from 3double-blind, randomized, placebo-controlled, published treatmenttrials: alprazolam for patients with premenstrual syndrome (PMS)and diazepam and lorazepam for patients with generalized anxietydisorder (GAD). The PMS group provided prospective daily symptomratings, which allowed ongoing investigation of effects of priortreatment. In the GAD groups, taper outcome was examined after 8weeks of benzodiazepine therapy as a function of priorbenzodiazepine use and as a function of time since last priorbenzodiazepine use. Symptom scores were analyzed using tstatistics in the PMS group and analysis of covariance with8-week scores as the covariate in the GAD groups.

Results: The PMS subjects reported no increasein symptom scores and no significant difference fromplacebo-treated subjects during taper and discontinuation ofalprazolam in the follicular phase of each treatment cycle. Inthe GAD trials, the results of treatment discontinuation did notdiffer significantly as a function of presence or absence ofprior benzodiazepine use or as a function of time since lastbenzodiazepine use.

Conclusion: These preliminary data failto support the hypothesis that prior benzodiazepine usepredisposes patients to more severe discontinuation symptoms whentreatment is brief and doses are low.

Volume: 61

Quick Links: Anxiety , Panic Disorder

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Clinical and Practical Psychopharmacology

Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia

Dr Andrade discusses whether or not recent findings support the use of NAC as antipsychotic augmentation in...

Read More...